Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Core Insights - Bolt Biotherapeutics is advancing its Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC candidate targeting claudin 18.2, with initial strong immune responses observed [1][4] - The company plans to modify the clinical trial protocol to allow for step-up dosing, which has been effective in commercial applications for T-cell engagers [1] - Initial clinical data for BDC-4182 is now expected to be reported in Q3 2026 [2][6] - To conserve capital and extend its cash runway into 2027, the company is implementing a workforce reduction of approximately 50% [2][6] - The CEO expressed gratitude to affected employees and emphasized the strategic focus on advancing BDC-4182 and supporting ISAC collaborations to enhance shareholder value [3] Company Overview - Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment [4] - The company's pipeline includes BDC-4182, which is currently in a Phase 1 trial involving patients with gastric and gastroesophageal cancer [4] - Bolt has strategic collaborations with Genmab and Toray centered around its Boltbody™ ISAC platform technology and expertise in myeloid biology [4]